Smithkline Beecham Corporation

Other

Affinium Pharmaceuticals, Inc.

Howard Kallender

Stephanie Van Horn

John Timothy Lonsdale

Leslie Marie Palmer

Michael N Gwynn

Anna Lisa Lenox

Raymond Winfield Reichard

Christopher Michael Traini

Judith M Ward

Jason Craig Fedon

Daniel Robert Sylvester

Martin K R Burnham

Min Wang

Richard Lloyd Warren

Magdalena Zalacain

Patrick Vernon Warren

Deborah Dee Jaworski

David John Holmes

Sanjoy Biswas

Martin Karl Burnham

Karen Anne Ingraham

Damien McDevitt

Jianzhong Huang

Chi Young So

Karen M O'Dwyer

Walter E Dewolf, Jr

Marie J Mazzulla

Glenn Scott Van Aller

Lisa Kathleen Katz

Joshua West

Provided is a screening method for compounds affecting fatty acid biosynthesis, the method comprising: providing a reaction mixture comprising: an acyl carrier moiety or enzymes and precursors sufficient to generate the acyl carrier moiety; a bacterial enzymatic pathway comprising at least two consecutively acting enzymes selected from the group consisting of: malonyl-CoA:ACP transacylase, beta-ketoacyl-ACP synthase III, NADPH dependent beta-ketoacyl-ACP reductase, beta-hydroxylacyl-ACP dehydrase and enoyl-ACP reductase; and substrates and cofactors required for the operation of the enzymes; contacting the reaction mixture with a prospective bioactive agent; conducting a high throughput measurement of the activity of the enzymatic pathway; and determining if the contacting altered the activity of the enzymatic pathway.

High throughput screening method for biological agents affecting fatty acid biosynthesis

The invention provides fabZ polypeptides and polynucleotides encoding fabZ polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing fabZ polypeptides to screen for antibacterial compounds.

FabZ from Staphylococcus aureus

The invention provides EF-Tu polypeptides and polynucleotides encoding EF-Tu polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing EF-Tu polypeptides to screen for antibacterial compounds.

EF-Tu

The invention provides birA polypeptides and polynucleotides encoding birA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing birA polypeptides to screen for antibacterial compounds.

BirA from staphylococcus aureus

The invention provides ratC polypeptides and polynucleotides encoding ratC polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ratC polypeptides to screen for antibacterial compounds.

RATC from Streptococcus pneumoniae

The invention provides gidB polypeptides and DNA (RNA) encoding gidB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidB polypeptides to screen for antibacterial compounds.

gidB from Staphylococcus aureus

The invention provides gidB polypeptides and polynucleotides encoding gidB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidB polypeptides to screen for antibacterial compounds.

gidB

The invention provides topA polypeptides and polynucleotides encoding topA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing topA polypeptides to screen for antibacterial compounds.

TopA

The invention provides fabF polypeptides and polynucleotides encoding fabF polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing fabF polypeptides to screen for antibacterial compounds.

FabF from Staphylococcus aureus

Topoisomerase I polypeptides and DNA and RNA encoding such topoisomerase I polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such topoisomerase I for the treatment of infection, particularly bacterial infections. Antagonists against such topoisomerase I and their use as a therapeutic to treat infections, particularly bacterial infections are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to the presence of topoisomerase I nucleic acid sequences and the polypeptides in a host. Also disclosed are diagnostic assays for detecting polynucleotides encoding streptococcal topoisomerase I and for detecting the polypeptide in a host.

Topoisomerase I

The invention provides gidA1 polypeptides and polynucleotides encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.

GidA1

The invention provides gidA1 polypeptides and DNA (RNA) encoding gidA1 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gidA1 polypeptides to screen for antibacterial compounds.

Growing community of inventors

Wayne, PA, United States of America

Howard Kallender